WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced preliminary revenue results for the third quarter of 2007. The Company expects to record total revenues of approximately $15.5 million in the third quarter of 2007, compared to $12.4 million in total revenues in the third quarter of 2006. This increase reflects the Company’s acquisition of ANTARA® (fenofibrate) capsules in August 2006, halfway through the third quarter.
